Zofran Lawsuit Plaintiffs Answer Questions Of Fact Regarding Birth Defect Allegations

December 30, 2015 – – ZofranLegal.com reports on questions of fact for plaintiffs involved in Zofran birth defect multidistrict litigation number 2657. Questions of fact are those questions which are asked to determine what happened that ultimately led to each plaintiff’s lawsuit. Questions of fact in Zofran lawsuits touch on topics ranging from birth defects, to unlawful product promotion, the hiding of evidence, and failure to warn the public about the side effects and dangers of the drug.

Cases involved in MDL 2657 were consolidated by the U.S. Judicial Panel on Multidistrict Litigation on October 13th of 2015. Lawsuits involved were filed against pharmaceutical conglomerate GlaxoSmithKline, and all contain the same questions of fact and allegations.

Questions of fact regarding the Zofran birth defect lawsuits will all be addressed at trial, however, at this time, trial dates have yet to be announced as much legal preparation is necessary first. The drug in question has now been linked to birth defects by plaintiffs as well as multiple studies.

In 1991, GSK gained approval to release Zofran to market from the U.S. Food and Drug Administration. This approval has become a point of contention for those involved in the lawsuits due to the fact that the drug was never approved to treat pregnant women for morning sickness. Instead, the anti-nausea drug was specifically approved to treat patients experiencing bouts of nausea and vomiting after undergoing chemotherapy, radiation, or anesthesia.

Despite this fact, after gaining FDA-approval, GSK began to market Zofran “off-label” as a morning sickness treatment to pregnant women and Ob/Gyns across the United States. Some plaintiffs claim that this “off-label” marketing continued despite many reports of Zofran exposure causing birth defects in developing fetuses.

Beginning in 2014, when the first Zofran birth defect lawsuit was filed against GSK, parents have continued to step forward alleging much the same. As these cases await trial, many anticipate that many others will be filed, due to the sheer volume of Zofran prescriptions currently given to expectant mothers.

The attorneys at Monheit Law understand the devastation that a lifelong or fatal birth defect can cause everyone involved. They are working to help ensure that anyone who took Zofran while pregnant and who subsequently gave birth to a child with defects will have the opportunity to explore their legal rights. These women and their affected children may be eligible for significant compensation. Monheit Law is currently offering complimentary consultations for anyone involved.

To request additional information or ask questions, contact Michael Monheit, Esq., lead attorney at Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60006825